<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527888</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-15-II</org_study_id>
    <nct_id>NCT03527888</nct_id>
  </id_info>
  <brief_title>Study of Anlotinib in Patients With Primary Malignant Bone Tumors</brief_title>
  <official_title>A Single-Arm, Open-Label, Multicenter Clinical Trial With Anlotinib Hydrochloride Capsule for Primary Malignant Bone Tumors With Recurrence and Distant Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of patients with recurrent and metastatic bone tumors.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress free survival (PFS)</measure>
    <time_frame>through study completion, an average of 6 month</time_frame>
    <description>From random grouping to the objective progression or death of a tumor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>through study completion, an average of 10 month</time_frame>
    <description>The time in which the group begins to cause death for any reason</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Neoplasm of Bone</condition>
  <arm_group>
    <arm_group_label>Anlotinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
    <arm_group_label>Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient volunteered to participate in this study and signed an informed consent;

          2. Pathological diagnosis of osteosarcoma, chondrosarcoma, source of undifferentiated
             pleomorphic sarcoma / malignant fibrous histiocytoma, derived bone giant cell tumor of
             bone or bone primary Ewing's sarcoma / primitive neuroectodermal tumor (PNET) tumor;

          3. All patients were failed in chemotherapy (including anthracycline) or intolerance,
             recurrence or distant metastasis, and at least one measurable lesion (according to
             RECIST 1.1 criteria);

          4. At the age of 14-70, less than 18 year old patients with body surface area to more
             than 1.5m2;

          5. ECOG PS score: 0~1 score (amputation patient's PS score is 0~2), and the expected
             survival time is over March;

          6. The main organs function within 7 days before the treatment, in accordance with the
             following criteria: the standard of blood routine examination (in 14 days without
             blood transfusion): The hemoglobin is greater than or equal to 90g/L (by multiple
             tumor metastasis induced anemia, hemoglobin = 85g/L); The neutrophil absolute value is
             more than 1.5 * 109/L; Platelet over 80 * 109/L. biochemical examination should comply
             with the following criteria: The total bilirubin is less than or equal to 1.5 Long
             ULN; The alanine aminotransferase and aspartate aminotransferase is less than or equal
             to 2.5ULN, such as liver metastasis, ALT and AST = 5ULN; The serum creatinine or
             creatinine clearance rate is greater than 1.5ULN 60ml/min; Doppler ultrasound
             assessment of the lower limit of normal value is more than the left ventricular
             ejection fraction (50%).

          7. Women of childbearing age should use contraceptive measures must be agreed within 6
             months in the study period and after the end of the study (such as IUD, pill or
             condoms); in the study before entering the group within 7 days of serum or urine
             pregnancy test is negative, and must be for patients with non lactation; men should
             agree to use contraceptive measures must be 6 months in the research period and the
             end of the study period after the patients.

        Exclusion Criteria:

        - Patients with immunodeficiency, including HIV positive or other acquired, congenital
        immunodeficiency disease, or organ transplant history Hypertension (systolic BP ≥150 mmHg,
        diastolic BP ≥90 mmHg) still uncontrollable by one medication Hepatitis B virus patients
        with active replication (DNA&gt; 500 cps / mL), hepatitis C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Yao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai 6th People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Jishuitan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100035</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai No.6 People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of the Air Force Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2018</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

